Skip to main content

Table 4 Clinical validity: known-group comparisons of the Taiwan Chinese EORTC QLQ-C30 and QLQ-CR29

From: Validation of the Taiwan Chinese version of the EORTC QLQ-CR29 to assess quality of life in colorectal cancer patients

Scale

Treatment

 

ECOG Status Score

 

Bristol Stool Scale

 

Active treatment

Follow-up

P-value&

ECOG = 0

ECOG = 1,2,3

P-value&

BSS = 0,1,2,3,4

BSS = 5,6

P-value&

n = 53

n = 55

 

n = 81

n = 27

 

n = 55

n = 53

 

QLQ-C30 function

 QL2

57.5

70.3

0.005

66.6

54.7

0.018

61.4

66.5

0.279

 PF

83.5

80.3

0.233

87.3

67.3

0.000

81.9

81.8

0.774

 RF

75.5

83.6

0.112

84.0

68.5

0.015

77.5

81.8

0.544

 EF

81.0

80.8

0.783

81.5

78.7

0.384

79.9

81.9

0.821

 CF

81.1

78.3

0.529

81.3

74.7

0.113

77.8

81.7

0.264

 SF

74.5

81.8

0.081

80.4

71.3

0.062

74.1

82.4

0.049

QLQ-C30symptom

 FA

31.7

29.1

0.717

26.4

42.5

0.001

31.1

29.6

0.698

 NV

9.4

7.0

0.570

8.1

8.6

0.958

10.3

6.0

0.064

 PA

18.2

16.1

0.734

15.0

24.1

0.020

18.5

15.7

0.400

 DY

10.9

15.2

0.306

12.5

15.4

0.278

11.1

15.1

0.359

 SL

21.4

27.7

0.321

23.6

26.9

0.836

23.0

26.1

0.512

 AP

21.4

11.5

0.063

13.8

24.7

0.041

21.2

11.3

0.034

 CO

23.3

25.3

0.601

21.1

33.3

0.032

22.2

26.4

0.310

 DI

25.2

21.4

0.881

24.6

20.0

0.637

24.7

21.8

0.476

 FI

15.1

15.1

0.910

15.4

13.3

0.996

17.3

12.8

0.334

QLQ-CR29 function

 BI

86.5

86.8

0.819

86.2

88.9

0.693

87.7

85.6

0.359

 ANX

58.3

67.3

0.061

63.7

60.0

0.490

62.3

63.4

0.948

 WEI

75.6

73.6

0.691

73.4

78.7

0.427

76.5

72.5

0.354

 SEXF

15.6

19.3

0.444

21.5

5.3

0.000

15.3

19.7

0.446

QLQ-CR29 symptom

 UF

22.8

20.4

0.781

17.3

34.0

0.001

22.8

20.3

0.644

 BMS

19.3

4.4

0.000

11.1

14.0

0.661

13.5

9.8

0.744

 SF2

22.2

19.3

0.852

19.9

23.3

0.796

21.7

19.7

0.850

 UI

5.1

7.5

0.971

6.3

5.3

0.842

5.6

7.2

0.750

 DY2

3.2

1.9

0.451

3.0

1.3

0.434

3.7

1.3

0.169

 AP2

13.5

14.5

0.426

14.3

13.3

0.479

11.7

16.3

0.110

 BP

12.0

8.2

0.277

9.3

13.0

0.865

12.2

7.8

0.203

 BF

21.2

19.9

0.980

20.5

20.0

0.612

18.5

22.7

0.213

 DM

31.4

26.4

0.205

28.3

30.7

0.529

27.2

30.7

0.267

 HL

19.2

15.7

0.469

18.6

14.7

0.450

19.5

15.3

0.950

 TA

9.6

12.8

0.596

13.2

5.3

0.133

11.3

11.1

0.916

 FL

21.3

22.2

0.866

20.4

26.7

0.346

17.3

26.5

0.059

 FI2

8.7

12.4

0.390

12.0

6.7

0.204

10.3

10.9

0.901

 SS

9.7

6.7

0.389

6.5

13.3

0.123

8.8

7.5

0.514

 EMB

14.3

13.1

0.616

13.1

16.0

0.516

11.8

15.6

0.514

 STO

11.1

0.0

0.138

3.3

11.1

0.418

0.0

6.7

0.500

 IMP

17.1

25.0

0.100

18.9

23.8

0.894

21.5

19.0

1.000

 DYS

11.9

8.0

0.417

12.6

0.0

0.071

9.3

9.5

0.889

  1. QL2 global health/quality of life, PF physical function, RF role function, EF emotion function, CF cognitive function, SF social function, FA fatigue, NV nausea/vomiting, PA pain, DY dyspnea, SL insomnia, AP appetite loss, CO constipation, DI diarrhea, FI financial difficulty, BI body image, ANX anxiety, WEI weight, SEXF sexual interest, UF urinary frequency, BMS blood and mucus in stool, SF2 stool frequency, UI urinary incontinence, DY2 dysuria, AP2 abdominal pain, BP buttock pain, BF bloating, DM dry mouth, HL hair loss, TA taste, FL flatulence, FI2 faecal incontinence, SS sore skin, EMB embarrassment, STO stoma care problem, IMP importance, DYS dyspareunia
  2. &Wilcoxon rank sum test. P-values in boldface indicate significant between-group difference in quality of life scores
  3. Quality of life scores presented as medium (interquartile range)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us